



SUGGESTED FORMULA

Buprenorphine Hydrochloride 0.5 mg/mL Transdermal

Version number: 1.0

Volume or quantity: 100mL

Buprenorphine Hydrochloride (CIII), USP (B1687)	0.05 gm
Ethoxy Diglycol (E1022)	x mL
Base, Liposome Cream (B1204)	Q.S. 100mL (94gm)*

*Specific gravity 0.94.

SUGGESTED COMPOUNDING PROCEDURES

1. Calculate the required quantity of each ingredient for the total amount to be prepared.
2. Weigh and/or measure each ingredient accurately.
3. In a mortar triturate the Buprenorphine Hydrochloride to a fine powder.
4. Add enough Ethoxy Diglycol to form a paste.
5. Geometrically incorporate the Liposome Cream into step 4, adding equal parts until the base is fully mixed.
6. Alternatively, you may mix ingredients with electronic mortar and pestle per pharmacy SOPs.
7. Transfer to dispensing syringes, click-pen or Topi-click Micro and label.
8. Suggested Quality assessments:
 - a. color
 - b. texture
 - c. no air bubbles
 - c. container
 - d. Label - auxiliary labels, storage, BUD, compounded medication

Store in air-tight container, at Controlled room temperature.

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date estimated to be 30 days

Precautions:

Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate protective equipment . Use safety enclosures (hoods) when weighing and mixing.

06/16rd